Taizhou Hanzhong biomedical

CompanyChina

Taizhou Hanzhong biomedical develops one asset, in phase 2 (HX008 in nonsquamous non small cell lung cancer). Mostly antibody acting on PDCD1; based in China.

Assets
1
Furthest
Phase 2
Trials
2
Signals
0

Pipeline

1

  • HX008

    Monoclonal antibody targeting PD-1

    Phase 2AntibodyPDCD1nonsquamous non small cell lung cancertriple-negative breast cancer (Phase 1)

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms2
  • Trials2
  • Similar companies6

Updated 7 Oct 2026 · 6 sources

Intelligence